Analysts: Macy’s Estimates Are Overly Optimistic and 3 More Research Notes to Look Through
Macy’s Inc. (NYSE:M): Maxim expects that Macy’s will report an in-line quarter but believes that the fiscal year 2014 Street earnings per share estimate of $4.32 is steep; instead, the firm expects fiscal year 2014 earnings per share of roughly $4.18. The firm believes that comps will be slower due to an expansion of the shop-in-shops being expanded next year, and the analyst has rated Macy’s shares a Hold.
ImmunoGen Inc. (NASDAQ:IMGN): Recent weakness is a buying opportunity, says Roth Capital. Roth remains encouraged by ImmunoGen’s partnership progress and for increased appreciation of its portfolio at ASH and throughout 2014. ImmunoGen shares are Buy rated.
Cirrus Logic Inc. (NASDAQ:CRUS): Northland defended Cirrus Logic following reports regarding the loss of two amplifiers in the iPad Air; the firm sees the loss as a negative but said that valuation is more attractive, especially considering that the company raised guidance on the September conference call. The analyst rates Cirrus Logic shares a Market Perform.
Sarepta Therapeutics Inc. (NASDAQ:SRPT): Piper Jaffray downgraded Sarepta two notches, to Underweight from Overweight, after the Food and Drug Administration reversed its appraisal of eteplirsen, calling the company’s new drug application on the existing Phase IIb data “premature;” Piper speculates that the FDA will require a confirmatory study with a two-year follow-up period, pushing the potential approval of the drug until late 2017/early 2018 from its prior expectation of late 2014. The firm lowered its price target for Sarepta shares to $20 from $58.
Don’t Miss: Cyrus Smokes Weed and Other Signs of the Times.